pentobarbital will lessen the level or influence of imatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.

pentobarbital will decrease the extent or influence of conivaptan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

Observe Closely (1)pentobarbital will lower the extent or influence of levamlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will decrease the extent or result of vardenafil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.

pentobarbital will decrease the extent or effect of isradipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.

pentobarbital will lessen the level or outcome of apremilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with solid CYP inducers ends in a substantial minimize of systemic exposure of apremilast, which can lead to lack of efficacy

pentobarbital will lower the extent or result of amlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

pentobarbital will lower the level or result of donepezil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unfamiliar.

pentobarbital will reduce the extent or impact of zolpidem by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unfamiliar.

Contraindicated. The therapeutic influence of elbasvir/grazoprevir could be diminished if coadministered with solid CYP3A inducers and is also for that reason contraindicated.

pentobarbital will minimize the level or outcome of terbinafine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

buprenorphine subdermal implant and pentobarbital both improve sedation. Steer clear of or Use Alternate Drug. Limit use to clients for whom choice therapy possibilities are insufficient

Just after stopping a CYP3A4 inducer, because the effects with the inducer drop, the fentanyl plasma focus will enhance which could increase or lengthen equally the therapeutic and adverse effects.

pentobarbital will lower the extent or impact of pimavanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Prevent coadministration if possible. Check for lessened pimavanserin efficacy. An increase in pimavanserin dosage could here possibly be needed.